The Time in Therapeutic Range and Bleeding Complications of Warfarin in Different Geographic Regions of Turkey: A Subgroup Analysis of WARFARIN-TR Study

Öz:

Anahtar Kelime:

Konular: Cerrahi

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. New Engl J Med 2003;349:1019-26.
2. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67.
3. White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007;167:239-45.
4. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-47.
5. Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011;106:968.
6. Cove CL, Hylek EM. An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes. J Am Heart Assoc 2013;2:e000136.
7. Pengo V, Pegoraro C, Cucchini U, Iliceto S. Worldwide management of oral anticoagulant therapy: the ISAM study. J Thromb Thrombolysis 2006;21:73-7.
8. Molteni M, Cimminiello C. Warfarin and atrial fibrillation: from ideal to real the warfarin affaire. Thromb J 2014;12:1.
9. Çelik A, İzci S, Kobat MA, Ateş AH, Çakmak A, Çakıllı Y, et al. The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: WARFARIN-TR. Anatol J Cardiol 2016;16:595-600.
10. Ertaş F, Kaya H, Kaya Z, Bulur S, Köse N, Gül M, et al. Epidemiology of atrial fibrillation in Turkey: preliminary results of the multicenter AFTER study. Turk Kardiyol Dern Ars 2013;41:99-104.
11. Turk UO, Tuncer E, Alioglu E, Yuksel K, Pekel N, Ozpelit E, et al. Evaluation of the impact of warfarin time in therapeutic range on outcomes of patients with atrial fibrillation in Turkey: Perspectives from the observational, prospective WATER Registry. Cardiol J 2015;22:567-75.
12. Singer DE, Hellkamp AS, Piccini JP, Mahaffey KW, Lokhnygina Y, Pan G, et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc 2013;2:e000067.
13. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ; American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):7-47.
14. Rosendaal FR, Cannegieter SC, Van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;69:236-9.
15. Wang Y, Kong MC, Lee LH, Ng HJ, Ko Y. Knowledge, satisfaction, and concerns regarding warfarin therapy and their association with warfarin adherence and anticoagulation control. Thromb Res 2014;133:550-4.
16. Asarcıklı LD, Şen T, İpek EG, Kafes H, Cebeci M, Gül M, et al. Time in therapeutic range (TTR) value of patients who use warfarin and factors which influence TTR. J Am Coll Cardiol 2013;62:127-8.
17. Cressman AM, Macdonald EM, Yao Z, Austin PC, Gomes T, Paterson JM, et al. Socioeconomic status and risk of hemorrhage during warfarin therapy for atrial fibrillation: A population-based study. Am Heart J 2015;170:133-40.
18. Sakarya A, İbişoğlu Ç. Türkiye'de illerin sosyo-ekonomik gelişmişlik endeksinin coğrafi ağırlıklı regresyon modeli ile analizi. Marmara Coğrafya Dergisi 2015:211-38.
19. Kilic S YE, Simsek E, Yagmur B, Soner HK, Akgü NM et al. Prospective observational comparison of TRW in patients followed by specialized INR outpatient clinic and by the general cardiology outpatient clinic. Anatol J Cardiol 2015;15(Suppl 1):1-104.
20. Okumura K, Komatsu T, Yamashita T, Okuyama Y, Harada M, Konta Y, et al. Time in the therapeutic range during warfarin therapy in Japanese patients with non-valvular atrial fibrillation-A multicenter study of its status and influential factors. Circ J 2011;75:2087-94.
21. Dlott JS, George RA, Huang X, Odeh M, Kaufman HW, Ansell J, et al. A national assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation. Circulation 2014;129:1407-14.

APA	Kilic S, Celik A, Cakmak H, AFŞİN A, TEKKEŞİN A, AÇIKSARI G, MEMETOĞLU M, KARADENIZ ÖZPAMUK F, ŞAHAN E, ALICI M, Dereli Y, SİNAN Ü, ZOGHİ M (2017). The Time in Therapeutic Range and Bleeding Complications of Warfarin in Different Geographic Regions of Turkey: A Subgroup Analysis of WARFARIN-TR Study. , 349 - 355.
Chicago	Kilic Salih,Celik Ahmet,Cakmak Huseyin Altug,AFŞİN ABDULMECİT,TEKKEŞİN Ahmet İlker,AÇIKSARI Gönül,MEMETOĞLU Mehmet Erdem,KARADENIZ ÖZPAMUK Fatma,ŞAHAN Ekrem,ALICI Mehmet Hayri,Dereli Yüksel,SİNAN ÜMİT YAŞAR,ZOGHİ Mehdi The Time in Therapeutic Range and Bleeding Complications of Warfarin in Different Geographic Regions of Turkey: A Subgroup Analysis of WARFARIN-TR Study. (2017): 349 - 355.
MLA	Kilic Salih,Celik Ahmet,Cakmak Huseyin Altug,AFŞİN ABDULMECİT,TEKKEŞİN Ahmet İlker,AÇIKSARI Gönül,MEMETOĞLU Mehmet Erdem,KARADENIZ ÖZPAMUK Fatma,ŞAHAN Ekrem,ALICI Mehmet Hayri,Dereli Yüksel,SİNAN ÜMİT YAŞAR,ZOGHİ Mehdi The Time in Therapeutic Range and Bleeding Complications of Warfarin in Different Geographic Regions of Turkey: A Subgroup Analysis of WARFARIN-TR Study. , 2017, ss.349 - 355.
AMA	Kilic S,Celik A,Cakmak H,AFŞİN A,TEKKEŞİN A,AÇIKSARI G,MEMETOĞLU M,KARADENIZ ÖZPAMUK F,ŞAHAN E,ALICI M,Dereli Y,SİNAN Ü,ZOGHİ M The Time in Therapeutic Range and Bleeding Complications of Warfarin in Different Geographic Regions of Turkey: A Subgroup Analysis of WARFARIN-TR Study. . 2017; 349 - 355.
Vancouver	Kilic S,Celik A,Cakmak H,AFŞİN A,TEKKEŞİN A,AÇIKSARI G,MEMETOĞLU M,KARADENIZ ÖZPAMUK F,ŞAHAN E,ALICI M,Dereli Y,SİNAN Ü,ZOGHİ M The Time in Therapeutic Range and Bleeding Complications of Warfarin in Different Geographic Regions of Turkey: A Subgroup Analysis of WARFARIN-TR Study. . 2017; 349 - 355.
IEEE	Kilic S,Celik A,Cakmak H,AFŞİN A,TEKKEŞİN A,AÇIKSARI G,MEMETOĞLU M,KARADENIZ ÖZPAMUK F,ŞAHAN E,ALICI M,Dereli Y,SİNAN Ü,ZOGHİ M "The Time in Therapeutic Range and Bleeding Complications of Warfarin in Different Geographic Regions of Turkey: A Subgroup Analysis of WARFARIN-TR Study." , ss.349 - 355, 2017.
ISNAD	Kilic, Salih vd. "The Time in Therapeutic Range and Bleeding Complications of Warfarin in Different Geographic Regions of Turkey: A Subgroup Analysis of WARFARIN-TR Study". (2017), 349-355.

APA	Kilic S, Celik A, Cakmak H, AFŞİN A, TEKKEŞİN A, AÇIKSARI G, MEMETOĞLU M, KARADENIZ ÖZPAMUK F, ŞAHAN E, ALICI M, Dereli Y, SİNAN Ü, ZOGHİ M (2017). The Time in Therapeutic Range and Bleeding Complications of Warfarin in Different Geographic Regions of Turkey: A Subgroup Analysis of WARFARIN-TR Study. Balkan Medical Journal, 34(4), 349 - 355.
Chicago	Kilic Salih,Celik Ahmet,Cakmak Huseyin Altug,AFŞİN ABDULMECİT,TEKKEŞİN Ahmet İlker,AÇIKSARI Gönül,MEMETOĞLU Mehmet Erdem,KARADENIZ ÖZPAMUK Fatma,ŞAHAN Ekrem,ALICI Mehmet Hayri,Dereli Yüksel,SİNAN ÜMİT YAŞAR,ZOGHİ Mehdi The Time in Therapeutic Range and Bleeding Complications of Warfarin in Different Geographic Regions of Turkey: A Subgroup Analysis of WARFARIN-TR Study. Balkan Medical Journal 34, no.4 (2017): 349 - 355.
MLA	Kilic Salih,Celik Ahmet,Cakmak Huseyin Altug,AFŞİN ABDULMECİT,TEKKEŞİN Ahmet İlker,AÇIKSARI Gönül,MEMETOĞLU Mehmet Erdem,KARADENIZ ÖZPAMUK Fatma,ŞAHAN Ekrem,ALICI Mehmet Hayri,Dereli Yüksel,SİNAN ÜMİT YAŞAR,ZOGHİ Mehdi The Time in Therapeutic Range and Bleeding Complications of Warfarin in Different Geographic Regions of Turkey: A Subgroup Analysis of WARFARIN-TR Study. Balkan Medical Journal, vol.34, no.4, 2017, ss.349 - 355.
AMA	Kilic S,Celik A,Cakmak H,AFŞİN A,TEKKEŞİN A,AÇIKSARI G,MEMETOĞLU M,KARADENIZ ÖZPAMUK F,ŞAHAN E,ALICI M,Dereli Y,SİNAN Ü,ZOGHİ M The Time in Therapeutic Range and Bleeding Complications of Warfarin in Different Geographic Regions of Turkey: A Subgroup Analysis of WARFARIN-TR Study. Balkan Medical Journal. 2017; 34(4): 349 - 355.
Vancouver	Kilic S,Celik A,Cakmak H,AFŞİN A,TEKKEŞİN A,AÇIKSARI G,MEMETOĞLU M,KARADENIZ ÖZPAMUK F,ŞAHAN E,ALICI M,Dereli Y,SİNAN Ü,ZOGHİ M The Time in Therapeutic Range and Bleeding Complications of Warfarin in Different Geographic Regions of Turkey: A Subgroup Analysis of WARFARIN-TR Study. Balkan Medical Journal. 2017; 34(4): 349 - 355.
IEEE	Kilic S,Celik A,Cakmak H,AFŞİN A,TEKKEŞİN A,AÇIKSARI G,MEMETOĞLU M,KARADENIZ ÖZPAMUK F,ŞAHAN E,ALICI M,Dereli Y,SİNAN Ü,ZOGHİ M "The Time in Therapeutic Range and Bleeding Complications of Warfarin in Different Geographic Regions of Turkey: A Subgroup Analysis of WARFARIN-TR Study." Balkan Medical Journal, 34, ss.349 - 355, 2017.
ISNAD	Kilic, Salih vd. "The Time in Therapeutic Range and Bleeding Complications of Warfarin in Different Geographic Regions of Turkey: A Subgroup Analysis of WARFARIN-TR Study". Balkan Medical Journal 34/4 (2017), 349-355.